Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial

Naifa L. Busaidy, Bhavana Konda, Lai Wei, Lori J. Wirth, Catherine Devine, Gregory A. Daniels, Jonas A. Desouza, Ming Poi, Nathan D. Seligson, Maria E. Cabanillas, Jennifer A. Sipos, Matthew D. Ringel, Ann Kathrin Eisfeld, Cynthia Timmers, Manisha H. Shah

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences